Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT001 Dose Finding in Mild to Moderate COPD
NCT00871182Phase 2Completed
- Sponsor
- Pearl Therapeutics
- Start
- Mar 2009
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glycopyrrolate metered dose inhaler in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Pearl Therapeutics. Primary endpoint: Peak improvement in forced expiratory volume in one second at Day 1. Started Mar 2009; status: completed.
02
Drugs
glycopyrrolate metered dose inhaler
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00871182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00871182.